Effects and Mechanisms of Combined Application of Molecular Targeted Drugs on Proliferation of Hepatocellular Carcinoma SK-Hep-1 Cells
10.3971/j.issn.1000-8578.2022.22.0157
- VernacularTitle:靶向药物联合应用对肝癌细胞SK-Hep-1增殖的影响及其机制
- Author:
Xiaoxia ZHU
1
;
Yuqi JIA
;
Chang LIU
;
Tao GONG
;
Gaopeng LI
;
Hongwei ZHANG
;
Baofeng YU
Author Information
1. Department of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan 030001, China
- Publication Type:Research Article
- Keywords:
Hepatocellular carcinoma;
Two-phase dynamics analysis;
Multi-driven proliferation;
Molecular targeted drug;
Mechanism of action;
Drug combination
- From:
Cancer Research on Prevention and Treatment
2022;49(11):1126-1133
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects and mechanisms of molecular targeted drug combination on multi-driven proliferation hepatocellular carcinoma SK-Hep-1 cells. Methods Four molecular targeted drugs (HG6-64-1, Dasatinib, Crizotinib, and Sunitinib) were used to treat SK-Hep-1 cells, and the monophasic kinetic analysis curve and two-phase analysis curve were drawn. Western blot analysis was used to detect the effects of the above drugs on key signaling pathways in SK-Hep-1 cells. MTT assay was used to detect the effects of the above drugs and their combination on the proliferation of SK-Hep-1 cells. Results Compared with the monophasic kinetic analysis curve, the biphase analysis curve could better fit the effects of molecular targeted drugs on SK-Hep-1 cells, which predicted that the combination of HG6-64-1, Dasatinib, and MK-2206 could effectively inhibit the proliferation of SK-Hep-1 cells. Conclusion Two-phase kinetic analysis can quantitatively describe the response of multi-driven proliferation hepatocellular carcinoma SK-Hep-1 cells to molecular targeted therapy. The combination of HG6-64-1, Dasatinib, and MK-2206 is a potential drug combination for the treatment of hepatocellular carcinoma.
